$5.01
+0.04(0.70%)
Mkt Cap $275M
$4.39
$7.02
52-Week Range
At a Glance
AI-generatedCandel Therapeutics, Inc.
8-K
Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025 on March 12, 2026. The announcement is furnished under Item 2.02 with Exhibit 99.1 press release attached.$275M
Market Cap
—
Revenue
-$38M
Net Income
Employees38
Fundamentals
How The Business Makes Money
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001841387
ISINUS1374041093
CUSIP137404109
Phone617 916 5445
Address117 Kendrick Street, Needham, MA, 02494, US
SEC EDGAR